Nuveen
KPTI icon

Nuveen’s Karyopharm Therapeutics KPTI Stock Holding History

Nuveen’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$370K Buy
+37,868
New +$328K ﹤0.01% 3417
2024
Q2 		– Sell
-32,824
Closed -$743K – 3379
2024
Q1 		$743K Buy
32,824
+2,537
+8% +$44.5K ﹤0.01% 2824
2023
Q4 		$393K Buy
30,287
+127
+0.4% +$1.71K ﹤0.01% 3080
2023
Q3 		$606K Sell
30,160
-742
-2% -$16.7K ﹤0.01% 2779
2023
Q2 		$830K Sell
30,902
-87,667
-74% -$3.78M ﹤0.01% 2734
2023
Q1 		$6.92M Buy
118,569
+12,322
+12% +$608K ﹤0.01% 1703
2022
Q4 		$5.42M Sell
106,247
-25,156
-19% -$1.74M ﹤0.01% 1863
2022
Q3 		$10.8M Buy
131,403
+5,044
+4% +$377K ﹤0.01% 1430
2022
Q2 		$8.55M Buy
126,359
+5,089
+4% +$467K ﹤0.01% 1616
2022
Q1 		$11.9M Buy
121,270
+42,316
+54% +$5.27M ﹤0.01% 1540
2021
Q4 		$6.71M Buy
78,954
+4,353
+6% +$434K ﹤0.01% 1933
2021
Q3 		$6.79M Sell
74,601
-1,127
-1% -$117K ﹤0.01% 2050
2021
Q2 		$11.7M Buy
75,728
+13,757
+22% +$2M ﹤0.01% 1764
2021
Q1 		$9.78M Sell
61,971
-6,535
-10% -$1.38M ﹤0.01% 1816
2020
Q4 		$15.9M Sell
68,506
-1,643
-2% -$381K 0.01% 1393
2020
Q3 		$15.4M Buy
70,149
+41,966
+149% +$10.3M 0.01% 1225
2020
Q2 		$8.01M Buy
28,183
+9,235
+49% +$2.73M ﹤0.01% 1637
2020
Q1 		$5.46M Sell
18,948
-11,875
-39% -$3.28M ﹤0.01% 1664
2019
Q4 		$8.86M Buy
30,823
+4,255
+16% +$923K ﹤0.01% 1657
2019
Q3 		$3.83M Buy
26,568
+854
+3% +$116K ﹤0.01% 2102
2019
Q2 		$2.31M Buy
+25,714
New +$2.06M ﹤0.01% 2369
2014
Q3 		– Sell
-725
Closed -$506K – 1616
2014
Q2 		$506K Buy
725
+30
+4% +$14K ﹤0.01% 1365
2014
Q1 		$322K Sell
695
-542
-44% -$275K ﹤0.01% 1417
2013
Q4 		$425K Buy
+1,237
New +$342K ﹤0.01% 1351

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen's KPTI Position: Q2 2026 in Review

Nuveen opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 37,868 shares worth $370K. The stake represents ﹤0.01% of the portfolio and ranks #3417 among its holdings. This is a return to the name: Nuveen previously reported a position in KPTI as recently as Q1 2024.

Nuveen first reported a position in KPTI in Q4 2013 and has held it in 24 quarters since. The position peaked at $15.9M in Q4 2020. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Nuveen held 37,868 shares of Karyopharm Therapeutics worth $370K as of Q2 2026.
  • Karyopharm Therapeutics was a new Nuveen position in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3417 holding.
  • Nuveen first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 24 quarters since.
  • Nuveen's Karyopharm Therapeutics position peaked at $15.9M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.